Fate, MSKCC expand off-the-shelf cell therapy deal

Memorial Sloan Kettering Cancer Center and Fate Therapeutics Inc. (NASDAQ:FATE) expanded a 2016 deal on Wednesday, granting Fate exclusive rights to additional IP that covers CAR constructs and off-the-shelf CAR T cells.

The existing deal, led by MKSCC Center for Cell Engineering Director Michel Sadelain, focuses on developing off-the-shelf T cell immunotherapies derived from engineered pluripotent cell lines. Under that agreement, Fate gained an exclusive license to IP covering induced pluripotent cell-derived immune cells, including T cells and NK cells derived from pluripotent cells engineered with CARs (see BioCentury Extra, Sept. 7, 2016)...